At the 2025 Annual Meeting of the American College of Clinical Pharmacology (ACCP) in Phoenix, Arizona, Prof David Burger chaired and spoke at the Symposium titled: Drug-Drug Interactions (DDIs) with Investigational Medicine Products: Can we do better?

Prof. Burger shared his experiences as a member of the Institutional Review Board (IRB), highlighting the challenges of incomplete and outdated DDI data. He discussed how these issues impact decision-making and offered suggestions for improving the quality and reliability of DDI information.

In addition to prof. Burger, prof. Amin Rostami (Univ of Manchester) discussed the role of PBPK modeling in improving DDI evaluation during drug development, and Dr. Thomas Kakuda (J&J Innovative Medicine), who reflected on his extensive experience in gathering DDI data during clinical drug development.

The symposium concluded with a clear message: Yes, we can do better. By sharing best practices and protecting investigational medicinal products from preventable DDIs.

Prof. Burger’s presentation can be found here DDI Management in Clinical Trials: Experiences from an IRB Member